Equity Overview
Price & Market Data
Price: $0.17
Daily Change: +$0.015 / 8.82%
Daily Range: $0.17 - $0.17
Market Cap: $89,734,160
Daily Volume: 101,125
Performance Metrics
1 Week: -13.89%
1 Month: -3.12%
3 Months: 346.0%
6 Months: 451.6%
1 Year: 109.5%
YTD: 157.7%
Details
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.